Clear Search

Showing 2 results for “autoimmune diseases” published 2023.

September 2023

Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune Diseases

J Pharmacol Exp Ther. 2023 doi: 10.1124/jpet.123.001744 Epub ahead of print

Preclinical evidence indicates a glucocorticoid (GC)-sparing potential for toll-like receptor (TLR)7/8 inhibitor compounds, suggesting TLR7/8i may offer a new strategy for the treatment of autoimmune diseases.

more…

February 2023

Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus

Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-222748

Post-hoc anaylsis of TULIP trials shows that, compared with placebo, anifrolumab treatment was associated with earlier, more frequent, and more prolonged and sustained lupus low disease activity state (LLDAS).

more…